Terlipressin for hepatorenal syndrome: Novel strategies and future perspectives

Frontiers of Gastrointestinal Research

Volumn 28, Issue , 2011, Pages 189-197

  Angeli, P ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; TERLIPRESSIN;

ARTERY COMPLIANCE; ARTICLE; ASCITES; BLOOD VOLUME; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART INFARCTION; HEART OUTPUT; HEPATORENAL SYNDROME; HUMAN; INTESTINE INFARCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FAILURE; NONHUMAN; PARACENTESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; SURVIVAL; TREATMENT RESPONSE; VASOCONSTRICTION;

EID: 79551486322     PISSN: 03020665     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000319000     Document Type: Article

References (48)

1. Schrier RW, Arroyo V, Bernardi M, et al: Peripheral arteriolar vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157.
2. Ruiz del Arbor L, Urman J, Fernandez J, et al: Systemic, renal and hepatic haemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218.
3. Ruiz del Arbor W, Urman J, Fernandez J: Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218.
4. Alqahtani SA, Fouad TR, Lee SS: Cirrhotic cardiomyopathy. Semin Liver Dis 2008;28:59-69.
5. Narahara Y, Kanazawa H, Taki Y, et al: Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1791-1797.
6. Guevara M, Gines P, Fernandez-Esparrach G, et al: Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
7. Gülberg V, Bilzer M, Gerbes AL: Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and albumin. Hepatology 1999;30: 870-875.
8. Ganne-Carrie N, Hadegue A, Mathurin P, et al: Hepatorenal syndrome: Long-term tretament with terlipressin as bridge to liver transplantation. Dig Dis Sci 1996;41:1054-1056.
9. Le Moine O, El Nawar A, Jagodzinski R, et al: Treatment with terlipressin as a bridge to translantation in a patient with hepatorenal syndrome. Acta Gastroenterol Belg 1998;61;268-270.
10. Duhamel C, Mauillon J, Berkelmans J, Bourienne A, Tranvuez JL: Hepatorenal syndrome in cirrhotic patients: Terlipressin is a safe and efficient treatment; propoanolol and digitalic treatment: Precipitating and preventing factors? Am J Gastroenterol 2000;95: 2984-2985.
11. Halimi C, Bonnard P, Bernard B. et al: Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: Results of a multicenter pilot study. Eur J Gastroenterol Hepatol 2002;14:153-158.
12. Mulkay JP, Louis H, Donckier V, et al; Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study. Acta Gastroelerol Belg 2001;64: 15-19.
13. Uriz J, Gines P, Cardenas A, et al: Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48.
14. Ortega R, Giniss P, Uriz J, et al: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002;36:941-948.
15. Solanki P, Chawala A, Garg R, et al: Beneficial effects of terlipressin in hepatorenal sindrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-156.
16. Moreau R, Durand F, Poynard T, et al: Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002;122:923-930.
17. Colle I, Durand F, Pessione F, et al: Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: A retrospective analysis. J Gastroenterol Hepatol 2002;17:882-888.
18. Angeli P, Guarda S, Fasolato S, et al: Switch therapy with ciprofloxacin versus intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: Similar efficacy at lower cost. Aliment Pharmacol Ther 2006;23:75-84.
19. Gerbes AL, Huber E, Gülberg V: Terlipressin for hepatorenal syndrome: Continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009;137:1179.
20. Angeli P, Volpin R, Gerunda G, et al: Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 1999;29:1690-1697.
21. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
22. Esrailian E, Pantageo ER, Kyulo NL, Hu KQ, Runyon BA: Octretide/midodrine therapy significantly improves renal function and 30- day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-748.
23. Skagen C, Einstein M, Lucey MR, Said A: Combination treatment with ocreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009;43:680-685.
24. Devoux C, Zanditenas D, Hezode C, et al: Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: A pilot study. Hepatology 2002;36:374-380.
25. Sharma P, Kumar A, Sharma BC, Sarin SK: An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-1697.
26. Gines P, Schier RW: Renal failure in cirrhosis. N Engl J Med 2009;361:1279-1290.
27. Sanyal A, Boyer T, Garcia-Tsao G, et al: A randomized, prospective, double blind placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368.
28. Martin-Llahi MM, Pepin MN, Guevara M, et al: Terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study. Gastroenterology 2008;134:1352-1359.
29. Gluud LL, Christensen K, Krag A: Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-584.
30. Angeli P: Review article: Prognosis of hepatorenal syndrome - has it changed with current practice? Aliment Pharmacol Ther 2004;20(suppl 3):1-4.
31. Restuccia T, Ortega R, Guevara M, et al: Effects of treatment of hepatorenal syndrome before transplantation on post- transplantation outcome: A case control study. Liver Transpl 2004;40:140-146.
32. Nezar A, Pereira GH, Guevara M, et al: Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010;51:219-226.
33. Fernandez J, Navasa M, Garcia-Pagan JC, et al: Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004;41: 384-390.
34. Meziani F, Kremer H, Tesse A, et al: Human serum albumin improves arterial dysfunction during early resuscitation in mouse endotoxic model via reduced oxidative and nitrosative stresses. Am J Pathol 2007; 171:1753-1761.
35. Angeli P, Fasolato S, Cavallin M, et al: Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 heptorenal syndrome (HRS) in patients with cirrhosis: Results of a controlled clinical study (abstract). Hepatology 2008;48(suppl):378A.
36. Escorsell A, Bandi JC, Moitinho E, Feu F, García-Pagan JC, Bosch J, Rodés J: Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997;26:621-627.
37. Testino G, Ferro C, Sumberaz A, et al: Type- 2 hepatorenal syndrome and refractory ascites: Role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003;50:1753-1755.
38. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M: Renal failure in cirrhotic patients: Role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-1368.
39. Moore KP, Wong F, Gines P, et al: The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-266.
40. Gines A, Fernandez-Esparrach G, Monescillo A, et al: Randomized controlled trial comparing albumin, dextran- 70 and polygelin in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-1010.
41. Ruiz del Arbor L, Monescillo A, Jimenez W, et al: Paracentesis- induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-586.
42. Vila MC, Solà R, Molina L, et al: Haemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol 1998;28:639-645.
43. Moreau R, Asselah T, Condat B, et al: Comparison of the effect of terlipressin and albumin on arterial volume in patients with cirrhosis and tense ascites treated by paracentesis: A randomized pilot study. Gut 2002;50:90-94.
44. Singh V, Dheerendra PC, Singh B, et al: Midodrine versus albumin in the prevention of paracentesisinduced circulatory dysfunction in cirrhotics: A randomized pilot study. Am J Gastroenterol 2008;103: 1399-1405.
45. Appenrodt B, Wolf A, Grünhage F, et al: Prevention of paracentesis-induced circulatory dysfunction: Midodrine vs albumin. A randomized pilot study. Liver Int 2008;28:1019-1025.
46. Russell JA, Walley KR, Singer J, et al: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887.
47. Morelli A, Ertmer C, Rehberg S, et al: Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): A randomized, controlled pilot study. Crit Care 2009;13:R130.
48. Moreau R, Barrière E, Tazi KA, et al: Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology 2002;36:1070-1078.